CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis

Published:2021-04 Issue:2 Volume:6 Page:100091
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Agostinetto E.^ORCID,Vian L.,Caparica R.,Bruzzone M.,Ceppi M.,Lambertini M.,Pondé N.,de Azambuja E.

Funder

AstraZeneca

Boehringer Ingelheim

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference23 articles.

1. Breast cancer statistics in the European Union: incidence and survival across European Countries;Dafni;Breast Care,2019

2. Breast cancer statistics, 2019;DeSantis;CA Cancer J Clin,2019

3. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials;Lancet,2015

4. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future;Spring;Lancet,2020

5. Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis;Brandão;ESMO Open,2020

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2- early breast cancer: a systematic review and meta-analysis;Frontiers in Pharmacology;2024-09-12

2. Cyclin-Dependent Kinase 4/6 Inhibitors as Neoadjuvant Therapy of Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: What do we Know so Far?;Clinical Breast Cancer;2024-04

3. The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials;Frontiers in Pharmacology;2024-01-15

4. Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2− breast cancer: an umbrella review;Journal of Cancer Research and Clinical Oncology;2024-01

5. Efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive breast cancer: a systematic review and meta-analysis;Expert Opinion on Pharmacotherapy;2023-09-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3